Loading...
•
Jun 30, 2023
Travere Q2 2023 Earnings Report
Travere Therapeutics reported its financial results for Q2 2023.
Key Takeaways
Travere Therapeutics reported a total revenue of $59.7 million for the second quarter of 2023, including $57.0 million in net product sales and $2.7 million in licensing and collaboration revenue. The company's cash, cash equivalents, and marketable securities totaled $491.3 million as of June 30, 2023.
Received 417 new patient start forms for FILSPARI in Q2 2023, indicating strong demand for IgAN treatment.
FILSPARI net product sales reached $3.5 million in Q2 2023 and $6.5 million in the first four and a half months post-approval.
Reported positive topline results from Cohort 6 in the Phase 1/2 COMPOSE Study of pegtibatinase in classical homocystinuria (HCU).
Announced an agreement to sell bile acid product portfolio for up to $445 million, strengthening financial foundation.
Revenue by Segment
Forward Guidance
Travere Therapeutics anticipates a review opinion by the Committee for Medicinal Products for Human Use (CHMP) on the potential approval of the Conditional Marketing Authorization (CMA) application for sparsentan for the treatment of IgAN in Europe around year-end. In late third quarter or early fourth quarter of 2023, the Company expects to report topline results from the two-year confirmatory endpoints in the ongoing Phase 3 PROTECT Study.
Positive Outlook
- Potential approval of sparsentan for IgAN in Europe by year-end.
- Topline results expected from Phase 3 PROTECT Study in late Q3 or early Q4 2023.
- Ongoing engagement with regulators on pivotal Phase 3 clinical trial design for pegtibatinase.
- Potential regulatory path forward for sparsentan in FSGS.
- Sale of bile acid product portfolio expected to close in Q3 2023
Challenges Ahead
- Uncertainty regarding the timing and outcome of regulatory reviews and approvals.
- Risks associated with the successful development and commercialization of FILSPARI.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...